IL316757A - Anti-CTLA-4 binding proteins and methods of using them - Google Patents
Anti-CTLA-4 binding proteins and methods of using themInfo
- Publication number
- IL316757A IL316757A IL316757A IL31675724A IL316757A IL 316757 A IL316757 A IL 316757A IL 316757 A IL316757 A IL 316757A IL 31675724 A IL31675724 A IL 31675724A IL 316757 A IL316757 A IL 316757A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- antibody
- ctla
- antigen
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785659P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316757A true IL316757A (en) | 2025-01-01 |
Family
ID=71126610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316757A IL316757A (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA-4 binding proteins and methods of using them |
| IL284156A IL284156B2 (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA–4 binding proteins and methods of using them |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284156A IL284156B2 (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA–4 binding proteins and methods of using them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12421311B2 (enExample) |
| EP (1) | EP3902821A4 (enExample) |
| JP (3) | JP7558949B2 (enExample) |
| KR (1) | KR20210121045A (enExample) |
| CN (2) | CN114008071B (enExample) |
| AU (2) | AU2019413366B2 (enExample) |
| BR (1) | BR112021012588A2 (enExample) |
| CA (1) | CA3124961C (enExample) |
| IL (2) | IL316757A (enExample) |
| MX (1) | MX2021007848A (enExample) |
| SG (1) | SG11202106764YA (enExample) |
| WO (1) | WO2020140084A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250157457A (ko) * | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| IL316757A (en) | 2018-12-27 | 2025-01-01 | Gigagen Inc | Anti-CTLA-4 binding proteins and methods of using them |
| AU2021299338A1 (en) * | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| AU2021411581A1 (en) * | 2020-12-31 | 2023-07-06 | Novarock Biotherapeutics, Ltd. | Antibodies to tnfr2 and uses thereof |
| EP4362981A1 (en) * | 2021-07-02 | 2024-05-08 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| KR20240114766A (ko) * | 2021-12-10 | 2024-07-24 | 머크 샤프 앤드 돔 엘엘씨 | 인간 메소텔린 결합제 |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US20110166335A1 (en) | 2000-06-30 | 2011-07-07 | Corbin David R | Xenorhabdus sp. genome sequences and uses thereof |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| EP1793858A4 (en) * | 2004-09-08 | 2008-12-10 | Univ Ohio State Res Found | HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2014089113A1 (en) | 2012-12-03 | 2014-06-12 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| WO2015092394A1 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| JP6449338B2 (ja) * | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| CA2976446A1 (en) | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| SI3303394T1 (sl) * | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| US10618960B2 (en) | 2015-12-15 | 2020-04-14 | Oncoimmune, Inc. | Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| WO2018157147A1 (en) | 2017-02-27 | 2018-08-30 | Dragonfly Therapeutics, Inc. | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 |
| JP7173993B2 (ja) * | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| IL316757A (en) | 2018-12-27 | 2025-01-01 | Gigagen Inc | Anti-CTLA-4 binding proteins and methods of using them |
| TWI850316B (zh) | 2019-01-21 | 2024-08-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
| AU2021299338A1 (en) | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
-
2019
- 2019-12-27 IL IL316757A patent/IL316757A/en unknown
- 2019-12-27 CN CN201980092796.9A patent/CN114008071B/zh active Active
- 2019-12-27 JP JP2021537082A patent/JP7558949B2/ja active Active
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 AU AU2019413366A patent/AU2019413366B2/en active Active
- 2019-12-27 CN CN202510014877.4A patent/CN119930820A/zh active Pending
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/pt unknown
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/es unknown
- 2019-12-27 CA CA3124961A patent/CA3124961C/en active Active
- 2019-12-27 US US17/418,776 patent/US12421311B2/en active Active
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en not_active Ceased
- 2019-12-27 IL IL284156A patent/IL284156B2/en unknown
- 2019-12-27 KR KR1020217023740A patent/KR20210121045A/ko active Pending
-
2024
- 2024-02-02 JP JP2024014900A patent/JP7745669B2/ja active Active
-
2025
- 2025-06-16 JP JP2025100129A patent/JP2025128343A/ja active Pending
- 2025-08-27 AU AU2025223772A patent/AU2025223772A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220064303A1 (en) | 2022-03-03 |
| IL284156B2 (en) | 2025-04-01 |
| MX2021007848A (es) | 2021-10-26 |
| EP3902821A1 (en) | 2021-11-03 |
| CN114008071B (zh) | 2025-01-21 |
| JP2022516071A (ja) | 2022-02-24 |
| JP2025128343A (ja) | 2025-09-02 |
| AU2019413366B2 (en) | 2025-06-05 |
| WO2020140084A1 (en) | 2020-07-02 |
| CA3124961A1 (en) | 2020-07-02 |
| JP7745669B2 (ja) | 2025-09-29 |
| IL284156A (en) | 2021-08-31 |
| SG11202106764YA (en) | 2021-07-29 |
| CN119930820A (zh) | 2025-05-06 |
| BR112021012588A2 (pt) | 2021-09-08 |
| KR20210121045A (ko) | 2021-10-07 |
| AU2019413366A1 (en) | 2021-08-12 |
| IL284156B1 (en) | 2024-12-01 |
| AU2025223772A1 (en) | 2025-09-18 |
| EP3902821A4 (en) | 2022-11-30 |
| CN114008071A (zh) | 2022-02-01 |
| US12421311B2 (en) | 2025-09-23 |
| JP2024042072A (ja) | 2024-03-27 |
| JP7558949B2 (ja) | 2024-10-01 |
| CA3124961C (en) | 2025-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3124961C (en) | ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USING THEM | |
| US20220064302A1 (en) | Anti-PD-1 Binding Proteins and Methods of Use Thereof | |
| WO2020140094A1 (en) | Anti-b7-h3 binding proteins and methods of use thereof | |
| US20230265192A1 (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| WO2020142626A1 (en) | Anti-ox40 binding proteins and methods of use thereof | |
| WO2022006555A2 (en) | BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE | |
| US20220056137A1 (en) | Anti-PD-L1 Binding Proteins and Methods of Use Thereof | |
| WO2020140070A1 (en) | Anti-b7-h4 binding proteins and methods of use thereof | |
| CA3249127A1 (en) | Anti-ctla-4 binding proteins and methods of use thereof |